MARKET

BTX

BTX

Brooklyn Immunotherapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

0.6601
-0.0549
-7.68%
After Hours: 0.6900 +0.0299 +4.53% 19:37 05/24 EDT
OPEN
0.7003
PREV CLOSE
0.7150
HIGH
0.7207
LOW
0.6414
VOLUME
283.88K
TURNOVER
0
52 WEEK HIGH
23.34
52 WEEK LOW
0.6414
MARKET CAP
37.92M
P/E (TTM)
-0.2409
1D
5D
1M
3M
1Y
5Y
Amarin Announces Appointment of New Directors and Board Leadership Changes
Erin Enright and Alfonso “Chito” Zulueta Appointed to Board of Directors New Board Members Bring Skills and Experience Aligned with the Company’s Strategy Per Wold-Olsen Named Chairman of the Board David Stack and Joe Zakrzewski to Retire from the Board Ac...
GlobeNewswire · 5d ago
BRIEF-Brooklyn Immunotherapeutics Inc Files For Offering Of Up To 13.7 Shares Of Common Stock By The Selling Stockholder - SEC Filing
reuters.com · 04/29 20:37
Brooklyn ImmunoTherapeutics stock rises ~7% on setting up of new R&D facility
Brooklyn ImmunoTherapeutics (NASDAQ:BTX) said it has set up a new corporate and research and development facility at The Boardwalk at Science Center Drive in San Diego, California to support translational
Seekingalpha · 04/21 12:56
Brooklyn ImmunoTherapeutics Announces Establishment Of New Research And Development Facility For Advancement Of Engineered Cellular Medicines
Brooklyn ImmunoTherapeutics, Inc. (NASDAQ:BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating
Benzinga · 04/21 11:33
Brooklyn ImmunoTherapeutics stock down ~12% after Q4 2021 results
Shares of Brooklyn ImmunoTherapeutics (NASDAQ:BTX) have fallen 11.9% on Monday in afternoon trading, after the clinical-stage biopharmaceutical company reported on April 15 its Q4 and FY 2021 results. BTX stock
Seekingalpha · 04/18 18:03
Brooklyn ImmunoTherapeutics Shares Slide After Company Reports Q4 Loss
MT Newswires · 04/18 15:24
Brooklyn Immunotherapeutics GAAP EPS of -$0.16
Brooklyn Immunotherapeutics press release (NASDAQ:BTX): Q4 GAAP EPS of -$0.16. As of December 31, 2021, Brooklyn had ~$17.0M in cash, compared to $1.6M as of December 31, 2020.
Seekingalpha · 04/18 07:58
BRIEF-Brooklyn Immunotherapeutics Announces Closing Of $12 Mln Private Placement
reuters.com · 03/09 21:23
More
No Data
Learn about the latest financial forecast of BTX. Analyze the recent business situations of Brooklyn Immunotherapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
100.00%Buy
0.00%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average BTX stock price target is 4.500 with a high estimate of 5.00 and a low estimate of 4.000.
High5.00
Average4.500
Low4.000
Current 0.6601
EPS
Actual
Estimate
-0.51-0.38-0.26-0.13
Q1 2021
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Institutional Holdings
Institutions: 63
Institutional Holdings: 12.86M
% Owned: 22.39%
Shares Outstanding: 57.45M
TypeInstitutionsShares
Increased
22
5.40M
New
15
2.35M
Decreased
9
38.90K
Sold Out
10
254.92K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.04%
Pharmaceuticals & Medical Research
+0.25%
Key Executives
Non-Executive Chairman/Independent Director
Charles Cherington
President/Chief Executive Officer/Director
Howard Federoff
Chief Administrative Officer
Jay Sial
Chief Scientific Officer
Kevin D' Amour
Vice President - Finance
Sandra Gurrola
Other
Roger Sidhu
Independent Director
Erin Enright
Independent Director
Dennis Langer
Independent Director
Erich Mohr
Independent Director
Heather Redman
No Data
No Data
About BTX
Brooklyn ImmunoTherapeutics, Inc. (Brooklyn), formerly NTN Buzztime, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on cytokine-based therapies in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. Brooklyn is engaged in developing IRX-2, a cytokine-based therapy, to treat patients with head and neck cancer. IRX-2 is an allogeneic, reproducible, primary, human cell-derived Interleukin-2 (IL-2) therapeutic with multiple active cytokine components that act on various parts of the immune system, to activate the entire tumor microenvironment. In addition to IL-2, IRX-2 contains multiple human cytokines that promote or enhance an immune response. IRX-2 is administered as an injection around lymph node beds.

Webull offers kinds of Brooklyn Immunotherapeutics Inc stock information, including NASDAQ:BTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading BTX stock methods without spending real money on the virtual paper trading platform.